CLEAVE-seq: technology for determination of on- and off-target sites for DNA endonucleases

BRIEF DESCRIPTION OF A TECHNOLOGY

The CLEAVE-seq technology enables increased sensitivity, speed, scale and cost effectiveness in the detection of DNA double strand breaks induced by DNA endonucleases.

PURPOSE

Determination of on- and offtargets for DNA endonucleases (e.g. CRISPR-Cas9).

Selection of the most specific Cas9-gRNA candidate for *in vitro*, *ex vivo* and *in vivo* genome editing.

FIELDS OF APPLICATION

Genome editing; gene therapy; genetic engineering in plant or animal systems for industrial application; tools for fundamental research.

TECHNOLOGY READINESS

Technology validated in lab (TRL 4).

INTELLECTUAL PROPERTY

Patent application: WO2019217816 (A1). Applicants: Pioneer Hi-Bred International, Inc. (United States); Vilnius University (Lithuania).

INVENTORS

- Stephane DESCHAMPS
- Virginijus SIKSNYS
- Joshua K. YOUNG
- Mindaugas ZAREMBA

RELEVANT PUBLICATIONS

Young et al. (2019) Scientific Reports, doi: 10.1038/s41598-019-43141-6.



In vitro, ex vivo and in vivo genome editing



Dr. Mindaugas Zaremba Institute of Biotechnology, Life Sciences Center, Vilnius University E-mail: mindaugas.zaremba@bti.vu.lt Phone: +370 5 223 4357

Dr. Ramūnas Grigonis

Innovation Office, Department for Research and Innovation, Vilnius University E-mail: ramunas.grigonis@cr.vu.lt Phone: +370 5 268 7006



